Your browser is no longer supported. Please, upgrade your browser.
Settings
AADI [NASD]
Aadi Bioscience, Inc.
Index- P/E- EPS (ttm)-6.07 Insider Own0.10% Shs Outstand20.80M Perf Week5.12%
Market Cap589.64M Forward P/E- EPS next Y-14.91 Insider Trans- Shs Float5.18M Perf Month-10.24%
Income-18.50M PEG- EPS next Q-6.00 Inst Own10.90% Short Float2.15% Perf Quarter4.63%
Sales14.59M P/S40.42 EPS this Y82.30% Inst Trans20.07% Short Ratio0.29 Perf Half Y17.17%
Book/sh11.15 P/B2.63 EPS next Y-30.90% ROA-42.70% Target Price- Perf Year26.24%
Cash/sh1.83 P/C16.02 EPS next 5Y- ROE-45.00% 52W Range14.31 - 49.80 Perf YTD99.66%
Dividend- P/FCF- EPS past 5Y30.90% ROI-14.70% 52W High-42.15% Beta1.60
Dividend %- Quick Ratio16.90 Sales past 5Y- Gross Margin- 52W Low101.31% ATR2.00
Employees12 Current Ratio16.90 Sales Q/Q8.10% Oper. Margin- RSI (14)48.90 Volatility3.40% 6.17%
OptionableNo Debt/Eq0.00 EPS Q/Q-141.00% Profit Margin- Rel Volume0.05 Prev Close29.35
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume385.93K Price28.81
Recom2.00 SMA20-0.20% SMA50-5.84% SMA20016.27% Volume8,160 Change-1.84%
Sep-14-21Initiated Ladenburg Thalmann Buy $51
Sep-08-21Initiated Piper Sandler Overweight $45
Sep-20-21 08:30AM  
Sep-13-21 08:00AM  
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, ABI-009 (FYARRO) is a form of sirolimus bound to albumin. Aadi is evaluating ABI-009 in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was founded in 2011 and is headquartered in Pacific Palisades, California.